Biomimetic DNA nanoballs for oligonucleotide delivery
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Mi-Gyeong | - |
dc.contributor.author | Park, Joo Yeon | - |
dc.contributor.author | Shim, Gayong | - |
dc.contributor.author | Choi, Han-Gon | - |
dc.contributor.author | Oh, Yu-Kyoung | - |
dc.date.accessioned | 2021-06-22T19:22:24Z | - |
dc.date.available | 2021-06-22T19:22:24Z | - |
dc.date.issued | 2015-09 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.issn | 1878-5905 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/17405 | - |
dc.description.abstract | Here, we designed biomimetic DNA nanoballs for delivery of multiple antisense oligonucleotides (ASOs). DNA templates with ASOs-complementary sequences were amplified by rolling circle amplification (RCA). RCA products were loaded with two types of ASOs by hybridization, condensed using adenovirus-derived Mu peptide, and coated with hyaluronic acid (HA) for delivery into CD44-overexpressing tumor cells. HA-coated, Mu peptide-condensed, dual ASO-loaded DNA nanoballs (HMA nanoballs) showed considerable cellular entry of Cy5-incorporated RCA product DNA and fluorescent ASOs, whereas Mu peptide-condensed, dual ASO-loaded DNA nanoballs (MA nanoballs) revealed limited uptake. Dual ASOs, Dz13 and OGX-427, delivered by HMA nanoballs could reduce the levels of protein targets and exert anticancer effects. Enhanced tumor distribution was observed for fluorescent HMA nanoballs than the corresponding MA nanoballs. Upon intravenous co-administration with doxorubicin, HMA nanoballs exerted the greatest anti-tumor effects among the groups. These results suggest HMA nanoballs as a nanoplatform for sequence-specific delivery of multiple ASOs and other functional oligonucleotides. (c) 2015 Elsevier Ltd. All rights reserved. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.title | Biomimetic DNA nanoballs for oligonucleotide delivery | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1016/j.biomaterials.2015.04.037 | - |
dc.identifier.scopusid | 2-s2.0-84930814120 | - |
dc.identifier.wosid | 000357240900016 | - |
dc.identifier.bibliographicCitation | BIOMATERIALS, v.62, pp 155 - 163 | - |
dc.citation.title | BIOMATERIALS | - |
dc.citation.volume | 62 | - |
dc.citation.startPage | 155 | - |
dc.citation.endPage | 163 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Engineering, Biomedical | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.subject.keywordPlus | C-JUN | - |
dc.subject.keywordPlus | RNA INTERFERENCE | - |
dc.subject.keywordPlus | THERAPEUTICS | - |
dc.subject.keywordPlus | STABILITY | - |
dc.subject.keywordPlus | SYSTEM | - |
dc.subject.keywordPlus | HSP27 | - |
dc.subject.keywordPlus | DZ13 | - |
dc.subject.keywordAuthor | DNA nanoballs | - |
dc.subject.keywordAuthor | Rolling circle amplification | - |
dc.subject.keywordAuthor | Biomimetic condensation | - |
dc.subject.keywordAuthor | Antisense oligonucleotides | - |
dc.subject.keywordAuthor | Sequence-specific loading | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0142961215004123?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.